ANAnastasia Nijnik

Anastasia Nijnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anastasia Nijnik has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emergency myelopoiesis in murine arthritis results in cell-intrinsic changes in dendritic cell development and function

    by Lin Tze Tung, Roselyn R. Jiang, Bianca Pozzebon, Mathieu Mancini, Lucie Droin, Mitra Yousefi, Joo Eun (June) Kim, Marwah Mousa, Yue Liang, Connie M. Krawczyk, et al.

  • Open Access

    Increased Expression and Altered Functional Activities of Immune Receptors TREM1, PD-L1, and Others on Hematopoietic Progenitor Cells in a Mouse Model of Rheumatoid Arthritis

    by Johanna M Toth, Roselyn R. Jiang, Lin Tze Tung, Dania Shaban, Mathieu Mancini, Bianca Pozzebon, Joo Eun (June) Kim, Mitra Yousefi, Danielle Malo, Silvia M. Vidal, et al.

    Hematopoietic stem and progenitor cells (HSPCs) sustain the production of hundreds of billions of new cells per day to maintain our blood and immune system. In this process, HSPCs regulate the hematopoietic output by sensing and integrating diverse physiological cues. Thus, HSPCs express many receptors traditionally studied for their functions in the immune system, and this allows HSPCs to directly detect microbial compounds, endogenous danger signals, cytokines, and other inflammatory mediators. However, how the expression levels of such receptors on HSPCs change under chronic inflammation and how such changes alter HSPC functions and immune cell production remains unexplored. Working in a murine model of rheumatoid arthritis, we demonstrate the induction of microbial sensors TLR2 and CD14, orphan inflammatory receptor TREM1, and checkpoint receptor PD-L1 on HSPCs and particularly the myeloid progenitor cells in the arthritis-afflicted mice. Furthermore, we demonstrate that the stimulation of HSPCs through these receptors in culture can significantly alter the dynamics of cell expansion and differentiation, with distinct responses from HSPCs of arthritis-afflicted versus healthy control mice. We hypothesize that the induction and stimulation of HSPCs through these immune receptors under chronic inflammation may impact the output and functional properties of their immune cell progeny, positing HSPCs as central players in the pathogenic inflammatory responses of rheumatoid arthritis and potentially other chronic inflammatory diseases. HIGHLIGHTS: Hematopoietic progenitor cells in murine models of rheumatoid arthritis show an upregulation of immune receptors TREM1, PD-L1, TLR2, and CD14. Stimulation of murine hematopoietic stem and progenitor cells through these receptors in culture alters the dynamics of their expansion and differentiation. In such cultures, hematopoietic stem and progenitor cells from mice afflicted with rheumatoid arthritis show altered responses to stimulation as compared to healthy controls.

  • Top Cited Papers

    Engineering tough blood clots for rapid haemostasis and enhanced regeneration

    by Shuaibing Jiang, Guangyu Bao, Zhen Yang, Jing Wu, Xingwei Yang, Joo Eun June Kim, Roselyn Jiang, Ying Zhan, Alexander Nottegar, Yin Liu, et al.

    Blood clots are pivotal for haemostasis and regeneration1, but they are mechanically weak and form slowly2, posing risks for life-threatening haemorrhage and limiting broader applications3,4,5. These limitations are attributed to complex coagulation cascades, abundant mechanically ineffective cells and little structural polymers. Strategies that strengthen polymer networks are inapplicable to these highly cellularized materials. Here we report a strategy that rapidly crosslinks red blood cells into tough cytogels and integrates them within blood clots. The resulting engineered blood clots (EBCs) form within seconds and exhibit a 13-fold increase in fracture toughness, and a 4-fold improvement in adhesion energy compared with native clots. Experiments and modelling identify the rupture of mechanically integrated cells as a key toughening mechanism. In vivo studies demonstrate that EBCs can rapidly halt haemorrhage, promote tissue regeneration, mitigate inflammation and foreign body reactions, and prevent postoperative adhesion. The safety and efficacy of both autologous and allogeneic EBCs were also validated. Our strategy is applicable to a range of cells and polymers. This work may motivate the development and translation of highly cellularized materials for bleeding control, wound management, tissue repair and regenerative medicine.


  • Open Access

    Loss of MYSM1 deubiquitinase catalytic activity protects against MYC-driven B cell lymphoma via tumor intrinsic effects and indirect modulation of antitumor immunity

    by Dania Shaban, Viktoria Plackoska, Yue Liang, Nay Najm, Francis Robert, Sidong Huang, Anastasia Nijnik

    Background: MYC is an oncogenic transcription factor that is over-expressed, amplified, or otherwise dysregulated in over 50% of all cancers. This includes over 10% of diffuse large B-cell lymphomas (DLBCL), where MYC translocations are associated with a poor therapy response and inferior prognosis for the patients. However, because MYC lacks ligand-binding or catalytic domains, it is a highly challenging drug target, and there is a wide interest in novel approaches to inhibit MYC oncogenic functions. MYSM1 is a chromatin-binding deubiquitinase (DUB) that promotes gene expression by catalytically removing the histone H2AK119ub epigenetic mark. In recent work, we demonstrated that MYSM1 acts in cooperation with MYC to sustain the expression of oncogenic transcriptional programs in hematopoietic cells, identifying MYSM1 as a potential therapeutic target for MYC-driven malignancies. Results: Here, we show for the first time that the loss of MYSM1 DUB catalytic activity, without the loss of MYSM1 protein expression, is sufficient to protect against MYC-driven lymphoma in murine models. We characterize the impact of MYSM1 loss-of-function on tumor cell physiology and on antitumor immunity, examining the tumor-intrinsic and the immune cell-mediated mechanisms involved in the protection against the disease. Leveraging human cancer genome databases, we provide first evidence linking MYSM1 loss-of-function to reduced fitness of human lymphoma cell lines in culture and to more favorable clinical outcomes in cancer patients. Conclusions: Overall, our studies support pharmacological inhibition of MYSM1 DUB catalytic function as a novel therapeutic strategy for MYC-driven lymphoma and potentially other cancers.

  • Open Access

    Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells

    by Maximilien Lora, H. A. Ménard, Anastasia Nijnik, David Langlais, Marie Hudson, Inés Colmegna

    Low dose methotrexate (LD‐MTX) remains the gold standard in rheumatoid arthritis (RA) therapy. Multiple mechanisms on a variety of immune cells contribute to the anti‐inflammatory effects of LD‐MTX. Inflammatory signaling is deeply implicated in hematopoiesis by regulating hematopoietic stem and progenitor cell (HSPC) fate decisions; raising the question of whether HSPC are also modulated by LD‐MTX. This is the first study to characterize the effects of LD‐MTX on HSPC. CD34+ HSPC were isolated from healthy donors' non‐mobilized peripheral blood. Resting and/or cycling HSPCs were treated with LD‐MTX [dose equivalent to that used in RA patients]. Flow cytometry was performed to assess HSPC viability, cell cycle, surface abundance of reduced folate carrier 1 (RFC1), proliferation, reactive oxygen species (ROS) levels, DNA double‐strand breaks, p38 activation, and CD34+ subpopulations. HSPC clonogenicity was tested in colony‐forming cell assays. Our results indicate that in cycling HSPC, membrane RFC1 is upregulated and, following LD‐MTX treatment, they accumulate more intracellular MTX than resting HSPC. In cycling HSPC, LD‐MTX inhibits HSPC expansion by promoting S‐phase cell‐cycle arrest, increases intracellular HSPC ROS levels and DNA damage, and reduces HSPC viability. Those effects involve the activation of the p38 MAPK pathway and are rescued by folinic acid. The effects of LD‐MTX are more evident in CD34+ CD38High progenitors. In non‐cycling HSPC, LD‐MTX also reduces the proliferative response while preserving their clonogenicity. In summary, HSPC uptake LD‐MTX differentially according to their cycling state. In turn, LD‐MTX results in reduced proliferation and the preservation of HSPC clonogenicity.


  • Open Access

    Engineering tough blood clots for rapid hemostasis and enhanced regeneration

    by Jianyu Li, Shuaibing Jiang, Guangyu Bao, Zhen Yang, Xingwei Yang, Joo Eun Kim, Alexander Nottegar, Yin Liu, Zu-Hua Gao, Andrew Beckett, et al.

    Blood clots play a pivotal role for hemostasis and regeneration1, but are slow to form and mechanically weak. These limitations are attributed to complex coagulation cascades, a high content of mechanically ineffective cells, and a low content of structural polymers2. They pose a considerable risk for life-threatening hemorrhage and constrain the broader application of blood clots3-5. Overcoming these limitations is a critical challenge, as existing strategies focused on polymer networks are inapplicable to highly cellularized materials like blood clots. Here we show a strategy termed click clotting, which rapidly crosslinks living cells into tough cytogels through bioorthogonal click reactions. We demonstrate this strategy by directly crosslinking red blood cells into cytogels and incorporating them within blood clots. The resulting engineered blood clots (EBC) exhibit instantaneous clot formation (< 5 seconds), a 13-fold increase in fracture toughness, and a 4-fold improvement in adhesion energy compared to native blood clots. Experiments and computational modeling reveal a unique toughening mechanism based on cell rupture. In vivo studies show that EBC outperform clinically used products in managing non-compressible hemorrhage. Specifically, EBC can rapidly halt hemorrhage, promote tissue regeneration, mitigate inflammation and foreign body reactions, and prevent postoperative adhesion. Furthermore, our strategy is versatile and applicable to a range of cells and polymers. This work is expected to motivate the development and translation of highly cellularized materials for wound management, bleeding control, tissue repair and regeneration.

  • Open Access

    Trained Immunity Affecting Dendritic Cell Differentiation and Function in Rheumatoid Arthritis

    by Lin Tze Tung, Roselyn R. Jiang, Bianca Pozzebon, Mathieu Mancini, Lucie Droin, Mitra Yousefi, Joo Eun (June) Kim, Marwah Mousa, Yue Liang, Connie M Krawczyk, et al.

    Rheumatoid arthritis affects ∼0.5-1% of the adult population and results in joint inflammation, chronic pain, and many systemic comorbidities. Immune and inflammatory tissue damage is the main pathogenic mechanism in rheumatoid arthritis, and involves the hyperactivation of both innate and adaptive immune systems. Trained immunity has become well established as an important feature of the innate immune system that allows the host to mount functionally altered immune responses based on their previous history of immune exposures, independently of the classical adaptive immunological memory. However, the role of trained immunity in systemic autoimmune and inflammatory disorders remains poorly understood. In the current work, we demonstrate that emergency myelopoiesis is induced in chronic rheumatoid arthritis in murine models and acts not only to enhance innate immune cell numbers but also to produce functionally altered innate immune cells. Such effects are cell-intrinsic to hematopoietic stem and progenitor cells (HSPCs) and persist independently of the inflammatory disease milieu. Importantly, these trained immunity mechanisms impact not only macrophages but also dendritic cells, which are the major antigen presenting cells that bridge the innate and adaptive immune responses. ‘Trained’ dendritic cells show changes in global gene expression profiles, and significantly altered responses to recall immune stimulation and capacity for T cell activation. This study therefore represents the first demonstration of ‘dendritic cell trained immunity’ in rheumatoid arthritis.


  • Hematopoietic Stem Cell Fates and the Cellular Hierarchy of Mammalian Hematopoiesis: from Transplantation Models to New Insights from in Situ Analyses

    by Dania Shaban, Nay Najm, Lucie Droin, Anastasia Nijnik

    Hematopoiesis is the process that generates the cells of the blood and immune system from hematopoietic stem and progenitor cells (HSPCs) and represents the system with the most rapid cell turnover in a mammalian organism. HSPC differentiation trajectories, their underlying molecular mechanisms, and their dysfunctions in hematologic disorders are the focal research questions of experimental hematology. While HSPC transplantations in murine models are the traditional tool in this research field, recent advances in genome editing and next generation sequencing resulted in the development of many fundamentally new approaches for the analyses of mammalian hematopoiesis in situ and at single cell resolution. The current review will cover many recent developments in this field in murine models, from the bulk lineage tracing studies of HSPC differentiation to the barcoding of individual HSPCs with Cre-recombinase, Sleeping Beauty transposase, or CRISPR/Cas9 tools, to map hematopoietic cell fates, together with their transcriptional and epigenetic states. We also address studies of the clonal dynamics of human hematopoiesis, from the tracing of HSPC clonal behaviours based on viral integration sites in gene therapy patients to the recent analyses of unperturbed human hematopoiesis based on naturally accrued mutations in either nuclear or mitochondrial genomes. Such studies are revolutionizing our understanding of HSPC biology and hematopoiesis both under homeostatic conditions and in the response to various forms of physiological stress, reveal the mechanisms responsible for the decline of hematopoietic function with age, and in the future may advance the understanding and management of the diverse disorders of hematopoiesis. Graphical Abstract


  • Open Access

    B-cell intrinsic regulation of antibody mediated immunity by histone H2A deubiquitinase BAP1

    by Yue Liang, HanChen Wang, Noé Seija, Yun Hsiao Lin, Lin Tze Tung, Javier M. Di Noia, David Langlais, Anastasia Nijnik

    Introduction: BAP1 is a deubiquitinase (DUB) of the Ubiquitin C-terminal Hydrolase (UCH) family that regulates gene expression and other cellular processes, through its direct catalytic activity on the repressive epigenetic mark histone H2AK119ub, as well as on several other substrates. BAP1 is also a highly important tumor suppressor, expressed and functional across many cell types and tissues. In recent work, we demonstrated a cell intrinsic role of BAP1 in the B cell lineage development in murine bone marrow, however the role of BAP1 in the regulation of B cell mediated humoral immune response has not been previously explored. Methods and results: In the current study, we demonstrate that a B-cell intrinsic loss of BAP1 in activated B cells in the Bap1fl/flCγ1-cre murine model results in a severe defect in antibody production, with altered dynamics of germinal centre B cell, memory B cell, and plasma cell numbers. At the cellular and molecular level, BAP1 was dispensable for B cell immunoglobulin class switching but resulted in an impaired proliferation of activated B cells, with genome-wide dysregulation in histone H2AK119ub levels and gene expression. Conclusion and discussion: In summary, our study establishes the B-cell intrinsic role of BAP1 in antibody mediated immune response and indicates its central role in the regulation of the genome-wide landscapes of histone H2AK119ub and downstream transcriptional programs of B cell activation and humoral immunity.


  • Open Access

    Chromatin‐binding deubiquitinase MYSM1 acts in haematopoietic progenitors to control dendritic cell development and to program dendritic cell responses to microbial stimulation

    by Marwah Mousa, Yue Liang, Lin Tze Tung, HanChen Wang, Connie Krawczyk, David Langlais, Anastasia Nijnik

    Dendritic cells (DCs) are the most significant antigen presenting cells of the immune system, critical for the activation of naïve T cells. The pathways controlling DC development, maturation, and effector function therefore require precise regulation to allow for an effective induction of adaptive immune response. MYSM1 is a chromatin binding deubiquitinase (DUB) and an activator of gene expression via its catalytic activity for monoubiquitinated histone H2A (H2A‐K119ub), which is a highly abundant repressive epigenetic mark. MYSM1 is an important regulator of haematopoiesis in mouse and human, and a systemic constitutive loss of Mysm1 in mice results in a depletion of many haematopoietic progenitors, including DC precursors, with the downstream loss of most DC lineage cells. However, the roles of MYSM1 at the later checkpoints in DC development, maturation, activation, and effector function at present remain unknown. In the current work, using a range of novel mouse models (Mysm1flCreERT2, Mysm1flCD11c‐cre, Mysm1DN), we further the understanding of MYSM1 functions in the DC lineage: assessing the requirement for MYSM1 in DC development independently of other complex developmental phenotypes, exploring its role at the later checkpoints in DC maintenance and activation in response to microbial stimulation, and testing the requirement for the DUB catalytic activity of MYSM1 in these processes. Surprisingly, we demonstrate that MYSM1 expression and catalytic activity in DCs are dispensable for the maintenance of DC numbers in vivo or for DC activation in response to microbial stimulation. In contrast, MYSM1 acts via its DUB catalytic activity specifically in haematopoietic progenitors to allow normal DC lineage development, and its loss results not only in a severe DC depletion but also in the production of functionally altered DCs, with a dysregulation of many housekeeping transcriptional programs and significantly altered responses to microbial stimulation.